A Study of TQ-B3101 in Subjects With Relapsed or Refractory Anaplastic Large Cell Lymphoma (ALCL)
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate efficacy and safety of TQ-B3101 in subjects with
relapsed/refractory anaplastic large cell lymphoma (ALCL) .